Indira A. Brar

Infectious Disease

2799 W Grand Blvd
Detroit, MI 48202

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Implementation of a Best Practice Advisory-Based HIV Screening Program in the Emergency Department with Integrated Infectious Diseases: A Descriptive Study.

Implementation of a Best Practice Advisory-Based HIV Screening Program in the Emergency Department with Integrated Infectious Diseases: A Descriptive Study.

Journal: Open forum infectious diseases

Published: March 11, 2026

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials.

Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials.

Journal: Open forum infectious diseases

Published: November 17, 2025

A cross-sectional analysis of doxyPEP use and outcomes in Michigan, United States.

A cross-sectional analysis of doxyPEP use and outcomes in Michigan, United States.

Journal: International journal of STD & AIDS

Published: September 15, 2025

Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I.

Effectiveness of B/F/TAF in adults with HIV who are viremic with M184V/I.

Journal: AIDS research and therapy

Published: July 16, 2025

Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.

Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.

Journal: Medicine

Published: February 24, 2025

Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort study.

Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort study.

Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Published: January 14, 2025

Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort.

Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort.

Journal: Open forum infectious diseases

Published: January 02, 2025

Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting.

Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting.

Journal: Open forum infectious diseases

Published: December 19, 2024

Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.

Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis.

Journal: The lancet. HIV

Published: December 06, 2024

Prescribing Practices of Recommended Treatment for Trichomonas vaginalis and Chlamydia trachomatis After 2021 Sexually Transmitted Infection Treatment Guideline Update.

Prescribing Practices of Recommended Treatment for Trichomonas vaginalis and Chlamydia trachomatis After 2021 Sexually Transmitted Infection Treatment Guideline Update.

Journal: Sexually transmitted diseases

Published: May 06, 2024

ACTIV trials: cross-trial lessons learned for master protocol implementation.

ACTIV trials: cross-trial lessons learned for master protocol implementation.

Journal: Journal of clinical and translational science

Published: October 23, 2023

Vaccine coverage and factors associated with vaccine adherence in persons with HIV at an urban infectious disease clinic.

Vaccine coverage and factors associated with vaccine adherence in persons with HIV at an urban infectious disease clinic.

Journal: Human vaccines & immunotherapeutics

Published: April 28, 2023

Showing 1-12 of 41

Last Updated: 09/26/2026